India's CDMO Sector Poised for Growth as Pharma Diversifies Beyond China

The global pharmaceutical supply chain is undergoing a massive structural realignment as multinational companies move manufacturing footprints away from China. As regulatory scrutiny intensifies around Chinese giants like WuXi AppTec, Indian Contract Development and Manufacturing Organisations (CDMOs) are emerging as the primary beneficiaries of this strategic shift.

India Emerges as the Preferred Global Alternative

The transition away from Chinese manufacturing is not a sudden reaction to recent regulatory developments but a trend that began nearly two years ago. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, global pharmaceutical players have already initiated conversations to diversify their supply chains.

The inclusion of certain entities in regulatory lists has further accelerated this movement, making it clearer for global firms to de-risk their operations. Indian CDMOs are responding to this demand by aggressively scaling up operations and increasing capital expenditure (capex) to ensure they can meet the growing requirements of global drugmakers. Sai Life Sciences, for instance, already works with 19 of the top 25 global pharmaceutical companies, highlighting the trust being placed in Indian capabilities.

Sai Life Sciences Strategy: Aggressive Expansion and Revenue Shifts

To capitalize on this landmark opportunity, Sai Life Sciences has announced a significant capacity expansion plan. The company intends to invest between ₹1,100 crore and ₹1,300 crore by FY27. This expansion will be funded through a combination of internal accruals and debt, maintaining a healthy balance sheet.

A notable shift is visible in the company's revenue mix. Over the last four years, the contribution from large global pharmaceutical companies has nearly doubled, rising from 28% to 49%. This reflects a broader industry trend where "Big Pharma" is no longer just using India for clinical supplies but is increasingly moving toward commercial-scale manufacturing.

From Clinical Supplies to Commercial Scale

One of the most significant indicators of India's growing maturity in the CDMO space is the shift in the project pipeline. Historically, many global firms utilized Indian facilities primarily for clinical-stage supplies. However, there is a marked increase in late-stage development projects.

Sai Life Sciences reported that its portfolio of Phase III and pre-registration molecules has grown from six to eleven in the past year. This surge in Phase III molecules is a fundamental reflection of global pharma's confidence in using India for large-scale commercial production.

While the long-term outlook is bullish, industry experts caution that the benefits will materialize gradually. Because pharmaceutical manufacturing is heavily regulated, transferring products and securing new approvals takes significant time. Consequently, the full impact of the China-plus-one strategy may not reflect in immediate quarterly earnings but will drive sustained growth in the coming years.

Sai Life Sciences has maintained its revenue growth guidance of a 15-20% CAGR, expecting the second half of the current financial year to be stronger as new capacities come online.

Key Takeaways

  • Strategic De-risking: Global pharma companies are actively diversifying away from China toward India to mitigate regulatory and supply chain risks.
  • Commercial Transition: Indian CDMOs are evolving from providing clinical-stage supplies to handling high-value, commercial-scale manufacturing for global innovators.
  • Aggressive Investment: Major players like Sai Life Sciences are committing upwards of ₹1,100 crore toward capacity expansion to meet rising global demand.